Open Access

ARTICLE

Diagnostic Performance of Serum miR-586 and miR-493 in Patients with Osteosarcoma

by Hao Dang

Department of Orthopaedics and Traumatology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

* Corresponding Author: Hao Dang. Email:

Oncologie 2020, 22(1), 35-42. https://doi.org/10.32604/oncologie.2020.012485

Abstract

This study aimed to explore the expression and diagnostic performance of miR-586 and miR-493 in patients with osteosarcoma. We enrolled 63 patients with osteosarcoma treated between May 2016 and May 2019 as the experimental group and 55 healthy volunteers who underwent physical examination during the same period as the control group. We detected miR-586 and miR-493 expression in serum, normal bone tissue, and tumor samples. We also evaluated the relationship between clinical indicators and the miR-586 and miR-493 expression levels. The correlation between the serum and osteosarcoma tissue expression of miR-586 and miR-493 was examined by Pearson analysis. Furthermore, the diagnostic performance of miR-586 and miR-493 in osteosarcoma was determined by the ROC curve analysis. The experimental group had higher serum miR-586 expression levels and lowered serum miR-493 expression levels than the control group (p < 0.05 on both). In tumor tissues, the miR-586 expression level was higher, whereas the miR-493 expression level was lower than in normal bone tissues (p < 0.05). The serum and tumor tissue expression of miR-586 and miR- 493 had a positive correlation (p < 0.05). The AUC, cutoff level, sensitivity, and specificity of miR-586 for osteosarcoma were 0.8413, 66.435, 66.67, and 98.18, whereas those of miR-493 were 0.7763, 62.540, 82.53, and 78.18, respectively. Patients with osteosarcoma exhibited up-regulated miR-586 levels and downregulated miR-493 levels in serum and tumor tissues significantly.

---

Keywords

---